Trilaciclib for prophylaxis of chemotherapy-induced myelosuppression in solid tumor patients: a systematic review and meta-analysis

ObjectiveTo systematically evaluate the clinical benefit and safety of trilaciclib in solid-tumor patients receiving chemotherapy and to inform clinical practice.MethodsFollowing PRISMA guidelines and registered at PROSPERO (CRD420251053232), we searched PubMed, Embase and two other databases from i...

Descripción completa

Detalles Bibliográficos

Autores principales:	Ting Yang, Pengjie Yang, Danyang Meng, Yong Zhu, Benben Zhu
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2026-04-01
Colección:	Frontiers in Pharmacology
Materias:	chemotherapy chemotherapy-induced myelosuppression (CIM) randomized controlled trial (RCT) solid tumors trilaciclib
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1754502/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!